Published in:
Open Access 01-12-2023 | Attention Deficit Hyperactivity Disorder | Research
Home-based brain–computer interface attention training program for attention deficit hyperactivity disorder: a feasibility trial
Published in: Child and Adolescent Psychiatry and Mental Health | Issue 1/2023
Login to get accessAbstract
Background
Attention deficit hyperactivity disorder (ADHD) is a prevalent child neurodevelopmental disorder that is treated in clinics and in schools. Previous trials suggested that our brain–computer interface (BCI)-based attention training program could improve ADHD symptoms. We have since developed a tablet version of the training program which can be paired with wireless EEG headsets. In this trial, we investigated the feasibility of delivering this tablet-based BCI intervention at home.
Methods
Twenty children diagnosed with ADHD, who did not receive any medication for the preceding month, were randomised to receive the 8-week tablet-based BCI intervention either in the clinic or at home. Those in the home intervention group received instructions before commencing the program and got reminders if they were lagging on the training sessions. The ADHD Rating Scale was completed by a blinded clinician at baseline and at week 8. Adverse events were monitored during any contact with the child throughout the trial and at week 8.
Results
Children in both groups could complete the tablet-based intervention easily on their own with minimal support from the clinic therapist or their parents (at home). The intervention was safe with few reported adverse effects. Clinician-rated inattentive symptoms on the ADHD-Rating Scale reduced by 3.2 (SD 6.20) and 3.9 (SD 5.08) for the home-based and clinic-based groups respectively, suggesting that home-based intervention was comparable to clinic-based intervention.
Conclusions
This trial demonstrated that the tablet version of our BCI-based attention training program can be safely delivered to children in the comfort of their own home.
Trial registration This trial is registered at clinicaltrials.gov as NCT01344044